Cerus (CERS) Expected to Announce Earnings on Tuesday

Key Points

• Cerus (CERS) is set to release its Q2 2025 earnings on August 5th, with analysts forecasting a loss of ($0.02) per share and revenues of $51.80 million.
• In the previous quarter, Cerus reported a loss of ($0.04) EPS against expectations of ($0.05) and generated revenue of $43.24 million, falling short of the $47.44 million estimate.
• Institutional investors bolster their positions, with nearly 78.37% of Cerus stock owned by hedge funds, including significant increases from AQR Capital Management and Cubist Systematic Strategies.

Cerus (NASDAQ:CERS - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Tuesday, August 5th. Analysts expect Cerus to post earnings of ($0.02) per share and revenue of $51.80 million for the quarter.

Cerus (NASDAQ:CERS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. Cerus had a negative net margin of 10.23% and a negative return on equity of 34.81%. The firm had revenue of $43.24 million during the quarter, compared to the consensus estimate of $47.44 million. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Performance

Cerus stock traded down $0.01 during mid-day trading on Friday, reaching $1.27. The company had a trading volume of 1,111,950 shares, compared to its average volume of 841,232. The company has a quick ratio of 1.63, a current ratio of 2.32 and a debt-to-equity ratio of 1.15. Cerus has a 52 week low of $1.12 and a 52 week high of $2.54. The company has a 50 day moving average of $1.39 and a 200-day moving average of $1.48. The firm has a market cap of $242.77 million, a price-to-earnings ratio of -12.70 and a beta of 1.56.

Hedge Funds Weigh In On Cerus

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC lifted its holdings in shares of Cerus by 12.0% during the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock worth $4,479,000 after acquiring an additional 344,395 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Cerus by 291.6% during the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company's stock worth $1,986,000 after acquiring an additional 1,064,133 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Cerus by 152.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company's stock worth $145,000 after purchasing an additional 62,854 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cerus during the 1st quarter worth about $32,000. 78.37% of the stock is owned by institutional investors.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.